Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: Todd D. Wiener who wrote (615)	4/30/1999 7:52:00 AM
From: Jim Oravetz	Read Replies (2) \| Respond to of 783

Biochem Pharma: Will Hepatitis B Cure its Shares? Analyst: Eric Singer 4/16/99 The biotech industry is at the cusp of a major inflection point. More products are in late stage clinical trials than ever before and more products are currently undergoing review by the Food and Drug Administration. As more and more biotechnology companies begin to realize revenue from their products, share prices are poised to surge. In fact, biotechnology stocks have come to life over the past six months. After bottoming in October, the AMEX Biotechnology Index has appreciated by over 40%. Much of this gain has come from profitable biotechnology leaders Amgen (NASDAQ:AMGN - news) and Biogen (NASDAQ:BGEN - news) . One stock that has not benefited from the surge in the sector is Laval, Quebec-based Biochem Pharma (NASDAQ:BCHE - news) ..... fnews.yahoo.com ++++++++++++++ Not sure is this was posted before. This goes on the say that there are 350M people with Hep-B. Numbers are low in the US, however. II states that by 2001, HB drug has sales of $500M with 10-15% going to BCHE. If this % number is so, I would also agree that GLX should grab them; especially at these prices. Any comments on whether the royalties number is too low? PS. Just bought in at $22 yesterday, the future look upward from here ! Jim